# Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

> **NCT00000626** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 27 (—)

## Conditions studied

- HIV Infections
- Hodgkin's Disease

## Interventions

- **DRUG:** Vinblastine sulfate
- **DRUG:** Dacarbazine
- **DRUG:** Filgrastim
- **DRUG:** Bleomycin sulfate
- **DRUG:** Doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00000626
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1999-02
- **Target enrollment:** 27 (—)
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000626, "Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*